TFRC
Transferrin receptor protein 1
As of the edition of 20 October 2026, TFRC (transferrin receptor protein 1, UniProt P02786) has 4 drugs tested at it and 3 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P02786
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 24
- Disease areas
- Inherited and neonatal; Nervous system; Nutrition and metabolism; Skin and connective tissue; Bones, joints and muscles; Blood and lymph; Cancer; Immune system
- Registered trials of its drugs
- 12
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 1 |
| Status not established | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Pabinafusp alfa | Marketed | Phase 3 | none listed |
| AOC 1044 | Active | Phase 3 | none listed |
| A27.15 | Went quiet | Phase 1 | none listed |
| CX-2029 | Status not established | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| JCR Pharmaceuticals | Route B |
The other 2 companies at TFRC
In the product3 companies in all; 2 are not named here, and no score is.
See the 3 companies at TFRC, ranked, with the facts behind eachRequest access. Nothing is shown until you do.